KBC excellent points.

Also, it may still be that part of the drag on the RVX share price is the failure of ASSURE which burnt many people. Even though we know much more now about this drug and it all seems very promising I can imaging many investors being gun shy. BoM is based on 3 point MACE and we don't know much about apabetalone and 3 point MACE because of the small sample sizes in the combined trial.

As BDAZ posted Sarah's explanation of the division of the compounds I say keep them separate. This allows each company to address their own target markets with much more focus.

Even though I was very critical of Don in my previous post I am still very excitied by the science for both companies. 

GLTA

Toinv